Showing results (261-270 of 421) with videos related to
Sort By:
Pageof 43
Urology|March 26, 2014
Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshopJonathan P Jarow, Ian M Thompson, Paul G Kluetz, et al.Cancer Prevention Research (Philadelphia, Pa.)|May 1, 2015
Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention TrialSarah H Nash, Jeannette M Schenk, Alan R Kristal, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2013
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance StudyDaniel W Lin, Lisa F Newcomb, Elissa C Brown, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapyCarol M Moinpour, Katherine A Hayden, Joseph M Unger, et al.Journal of the National Cancer Institute|June 29, 2007
Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention TrialCarol M Moinpour, Amy K Darke, Gary W Donaldson, et al.The Prostate|August 27, 2015
Processing of voided urine for prostate cancer RNA biomarker analysisSue-Ing Quek, Olivia M Wong, Adeline Chen, et al.The Prostate|June 8, 2020
The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention TrialSusan Chadid, John R Barber, William G Nelson, et al.Journal of the National Cancer Institute|July 12, 2013
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trialTheodore M Brasky, Amy K Darke, Xiaoling Song, et al.Cancer Epidemiology|June 25, 2018
The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trialsJoseph M Unger, William E Barlow, Catherine M Tangen, et al.Cancer Causes & Control : CCC|July 20, 2012
Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention TrialSiobhan Sutcliffe, Cathee Till, Charlotte A Gaydos, et al.Pageof 43